Khaled was joined by a panel of adult and pediatric hematology-oncology experts who provided an overview of TA-TMA, including findings that raise suspicion of this complication, strategies they use for making the diagnosis, and how they intervene given limited treatment options. They also discussed some off-label treatments and the emerging treatment narsoplimab (OMS721), a human monoclonal antibody that is under review by the FDA.
TA-TMA is triggered by injury to endothelial cells, such as from radiation, use of calcineurin or mTOR inhibitors, infections, or chemotherapy. However, this first hit to the endothelial cells is not considered sufficient to cause TMA. A second hit is needed, which the panelists explained is activation of the complement system, a part of the immune system made up of many distinct plasma proteins that react with one another in a cascade to destroy pathogens and fight infection. The same factors that damage endothelial cells also activate the complement system, the panelists noted.
Injured endothelium exposes certain molecules, known as DAMPs [damage-associated molecular patterns], which bind a molecule known as MBL, mannan-binding lectin. MBL then activates MASP-2 [mannan-binding lectin-associated serine protease-2], which is an important enzyme in the cascade of a part of a complement system known as the lectin pathway. When activated, the lectin pathway itself can also then turn on the alternative path-way of complement. It is always on at very low levels waiting for a foreign invader or endothelial cell injury. Now you have marked activation of the lectin pathway and the complement pathway and the alternative pathway of complement in this system. If you cant shut it off and its progressive, that can lead to 1 of these TA-TMAs, Jeffrey Conrad Laurence, MD, explained.
The panelists said that there are some key differences with TA-TMA in pediatric vs adult patients. One distinction is that they are seen almost exclusively with allogeneic transplants in adults, whereas they occur with both autologous and allogeneic transplants in children. Only Khaled reported seeing a few cases in adults undergoing autologous transplants. At City of Hope we had a protocol for an autologous transplant for scleroderma, and I saw a couple of cases on that protocol, he said, noting that he has also seen 1 or 2 cases over the last 12 years in patients who received autologous transplants for myeloma.
Another key distinction is that TA-TMA in pediatric patients appears to have a genetic component, whereas in adults no gene polymorphisms appear to contribute to the condition. [In a study by Jodele et al1], upward of 30% to 40% of her pediatric patients who developed TMA had some recognized mutation in a complement coagulation or complement-regulatory factor gene. Whereas in our studies at Weill Cornell Medicine, we never found that. In many other series in adults, its incredibly rare to find those kinds of genetic mutations. There may be something special about that [pediatric] population with higher underlying inability to control complement that makes the incidence much greater, Laurence said.
Determining the incidence of TA-TMAs is challenging because diagnostic criteria did not exist until relatively recently and those now available also vary somewhat. In fact, it depends on whether you really want injury to happen and then make a diagnosis, or do you want early diagnosis. The more stringent the criteria you apply, the less the incidence will seem, Parameswaran Hari, MD, MRCP, said. Nevertheless, based on his experience, he suspects the incidence in adult patients to be in the 10% range for TA-TMAs that are of clinical consequence following a first allogeneic transplant. He noted that the incidence increases with a second transplant, reaching 15% to 20%.
In pediatric patients, the panelists noted the incidence is higher than in adults, ranging between 20% and 30%. When I think about the difference between the adult and pediatric populations and the incidence, one of the questions that comes to mind is: Is it a difference in the patients, is it a difference in the treatment, or is it a difference in the providers? Christine N. Duncan, MD, said. She explained its probably a combination of these factors, but that one of the main contributors is likely the screening criteria that were developed for children, which have helped raise awareness of the disease in the pediatric setting.
A variety of diagnostic criteria for TA-TMA now exist, including those by the LeukemiaNet International Working Group, Blood and Marrow Transplant Clinical Trials Network, and the Jodele criteria, among others.2-4 In pediatric patients, Duncan said there is relatively uniform acceptance of the Jodele criteria (Table4). Were looking if you can meet 4 of the 7 criteria...but we dont necessarily always say you have to meet all those points. If we have someone who has hypertension and proteinuria, were not going to wait and check everything else off to make sure they absolutely fulfill the criteria, Duncan said.
Table. Laboratory and Clinical Markers Indicating TMA per Jodele Criteria4
The other available diagnostic criteria look at many of the same measures, with some also examining additional markers, such as the direct Coombs test, which should be negative in the setting of TA-TMA; coagulation studies, which should be normal; haptoglobin levels, which may be decreased; and creatinine levels, which may point to TA-TMA when elevated to twice the baseline level.2,3 The panelists proceeded to discuss the clinical and laboratory markers that they pay particular attention to. Hari said lactate dehydrogenase (LDH) level is a big marker at his institution, which implemented a policy to check patients LDH levels twice weekly while they are in the hospital following transplantation. He said this measure has helped them identify more TA-TMA cases. On the pediatric side, Duncan said they also test LDH levels in all patients once or twice weekly. You dont even have to think about it much if that is part of your routine on an inpatient, and if you see that with your lab values, that helps to trigger [a diagnosis], she said. Duncan said another red flag in the pediatric setting is hypertension since this population rarely has it as a preexisting condition, though some degree of blood pressure elevation is expected from use of calcineurin inhibitors, steroids, and other agents.
Although ADAMTS13 activity is not part of any diagnostic criteria for TA-TMA, Laurence and Hari said they perform this test on all their transplant patients to help rule out thrombotic thrombocytopenic purpura (TTP). Making the distinction is important because patients with TTP can benefit from plasma exchange, whereas those with TA-TMA do not. I noticed that in 3 large transplant studies5 the aggregate hematologic response to plasma exchange in a TA-TMA was 55%; that included a decrease or normalization of the LDH, increase in haptoglobin, and increase in platelet count. That 55% response rate to plasma exchange had no impact on mortality...the patients died with normal numbers, Laurence said. He added that he no longer performs therapeutic plasma exchange for his TA-TMA patients.
One of the key treatment strategies for TA-TMA is to stop any offending agents, including any calcineurin or mTOR inhibitors. We recommend substituting higher doses of steroids and CellCept [mycophenolate mofetil], Laurence said. He explained another important measure is to look for and treat any underlying or coexisting conditions, such as infections, graft-vs-host disease (GVHD), or hypertension. The literature suggests these measures may be sufficient to resolve 50% to 60% of TA-TMA cases.6 The remainder require consideration of a variety of off-label or experimental agents, Laurence said, particularly agents that target the complement system, such as eculizumab (Soliris), defibrotide (Defitelio), or narsoplimab, since there are currently no approved treatments for TA-TMA and resolution of TA-TMA is imperative for improving overall survival (OS).
Eculizumab
Eculizumab is a monoclonal antibody that inhibits complement protein C5.7 It is approved by the FDA for the treatment of atypical hemolytic uremic syndrome (aHUS), another complement-mediated disease. [In TA-TMA,] its probably more used in pediatric population than in the adult population, Khaled said.
Thus far, eculizumab has been studied in a small clinical trial of 64 pediatric patients with high-risk TA-TMA and multiorgan injury.8 One year after hematopoietic stem cell transplantation (HSCT), the survival was 66% in the eculizumab-treated group. This was a significant improvement from the 16.7% survival rate observed in a previously reported untreated cohort that had the same high-risk TMA features. Patients with a higher sC5b-9 level at the start of eculizumab therapy were found to be less likely to respond to treatment and to require more drug doses.8
We use [eculizumab] quite frequently. If [a patient has received a diagnosis] of TA-TMA and has any degree of significance or injury to them, theres always a conversation, Duncan said. She noted that there are several key challenges with the use of eculizumab, including a lack of consensus on how long patients need to be treated, uncertainly regarding optimal dosing (eg, when to go up, how to space), and challenges receiving authorization for this drug in the outpatient setting. Additionally, its use requires prophylactic immunization and antibiotics against a variety of infectious organisms, including Neisseria meningitidis and N gonorrhea in adults, as well as a variety of encapsulated organisms in pediatric patients.7
Defibrotide
Defibrotide was approved by the FDA for the treatment of adult and pediatric patients with hepatic veno-occlusive disease (VOD) with renal or pulmonary dysfunction following hematopoietic stem-cell transplantation in 2016,9 but Hari said this drug has been used for decades in Europe. While its precise mechanism of action remains unknown, he said its an anti-inflammatory agent [that] can be thought of as an endothelial stabilizing agent.
Defibrotide has shown some promise in treating TA-TMA. There is definitely a subgroup of people who respond to itnot as promising as a dedicated mannose-binding lectin pathway inhibitor, perhaps, but I think that 1 hit of the endothelium might be able to be helped by this agent, Hari said. However, a challenge is its bleeding risk, which is especially problematic in a patient population that is already at high risk of hemorrhage. Cost is another issue. We dont use too much of [it], unless we have some evidence of liver damage, because of the payment issues, at least in this country, Hari said.
Narsoplimab
Narsoplimab is an inhibitor of MASP-2, which is the effector enzyme of the lectin pathway of the complement system.10 The FDA has granted this agent breakthrough therapy designation for high-risk HSCT-TMA and orphan drug designation for the prevention of complement-mediated TMAs and for the treatment of HSCT-TMA.10 The drugs manufacturer, Omeros Corporation, has submitted a biologics license application to the FDA for narsoplimab as a treatment of HSCT-TMA, and the FDA has extended its review period, setting a new action date of October 17, 2021.11
Narsoplimab has shown benefit in a small, single-arm, open-label pivotal trial that included 28 adult patients (median age, 48 years) with HSCT-TMA and high comorbidity burden.12,13 Protocol-specified treatment was IV narsoplimab 4 mg/kg or 370 mg once weekly for 4 or 8 weeks, with a 6-week follow-up period. The primary end point was complete response (CR) rate, which required improvement in 2 categories: laboratory markers of TMA (ie, LDH, platelet count) and organ function (ie, kidney, pulmonary, gastrointestinal [GI], neurological).
The complete response rate was actually very appealing: It was 61% of all treated patients and 74% for the per-protocol set....Those are the patients who received 4 weeks or more on protocols, Khaled said. Among both cohorts, 72% of patients showed substantial improvement in organ function, with greater than 65% showing improvements in kidney function, 50% showing improvements in neurological function, and 100% showing improvement in GI function.13
When looking at the median OS, it was 274 days for all treated patients and 361 days for the per-protocol patients, with the median OS not reached in patients who had a CR.12 This is really compelling data for this molecule, Khaled said. The other panelists agreed. I think the availability of a pathophysiologically targeted agent addresses what really is at the bottom of the problem, Hari said.
What makes the data even more compelling is that narsoplimab appears to have a highly favorable safety profile. Unlike eculizumab, it does not require the use of prophylactic immunization or antibiotics and it was found to be well-tolerated, even in a population with a high comorbidity burden. The most common adverse effects (AEs) included pyrexia, diarrhea, vomiting, nausea, neutropenia, fatigue, and hypokalemia, all of which are common in the setting of HSCT.12 In total, 6 patients died during the core study period, with the causes of death being common in HSCT (eg, septic shock, GVHD, TMA).
In addition to narsoplimab, several other agents are in late-stage development, including ravulizumab, a long-acting C5 inhibitor engineered from eculizumab. It is currently being studied in 2 phase 3 trials, including 1 in pediatric patients (NCT04557735) and 1 in adolescent ( 12 years) and adult patients (NCT04543591).14,15 Another promising agent is nomacopan (Coversin), a bifunctional inhibitor of C5 and leukotriene B4 that is being studied in a phase 3 trial in pediatric patients aged 6 months to 18 years who develop TMA within 100 days of HSCT, which is the period when most TMAs requiring intervention occur.16
In his concluding remarks, Laurence encouraged health care providers to think about the pathophysiology of TA-TMA when caring for their HSCT patients. Dont just tread water doing things like plasma exchange or Rituxan [rituximab] unless theres a specific indication for an autoantibody present. Think about trials of these newer experimental agents, which look very promising, he said.
View original post here:
Transplant-Associated Thrombotic Microangiopathy: New Insights, Emerging Treatments - OncLive
- Using stem cell-derived heart muscle cells to advance heart regenerative therapy - Medical Xpress - April 28th, 2024
- John Cleese is spending thousands on stem cell therapy is it really the secret to anti-ageing? - Yahoo Lifestyle Australia - April 28th, 2024
- SUM Hospital conducts Odishas first stem cell transplantation - The Times of India - April 24th, 2024
- Cancer treatment: What is stem cell therapy, and how does it work? - Moneycontrol - April 24th, 2024
- The murky, unregulated world of anti-ageing stem cell therapy - The Telegraph - April 24th, 2024
- Drug Prototype Promising in Treatment of Pulmonary Disease - Medscape - April 20th, 2024
- Man Paralyzed In Surfing Accident Regains Ability to Walk After Stem Cell Treatment - The Inertia - April 20th, 2024
- Medical breakthrough: 8-year-old boy first in New York to receive FDA-approved gene therapy for rare inherited blood disorder - WABC-TV - April 20th, 2024
- Stem Cell Treatment Helped A Man Who Was Paralyzed From The Neck Down To Stand On His Own - Bored Panda - April 20th, 2024
- UM, CUHK jointly hold symposium on stem cells and regenerative medicine - gcs.gov.mo - April 20th, 2024
- Paralysed patient now able to walk as stem cell therapy shows promising results - WION - April 15th, 2024
- Andrew Steele Sees Aging as the Root of Disease - Worth - Worth Magazine - April 15th, 2024
- The astonishing effect of stem cell implants - as groundbreaking treatment 'transforms' life for those with brain damage ... - Daily Mail - April 15th, 2024
- Consumer Alert on Regenerative Medicine Products Including Stem Cells - FDA.gov - April 13th, 2024
- This Startup Wants To Be OpenAI Of Stem Cell Therapy, Targets $250B Market - Forbes - April 13th, 2024
- Brain-cell transplants are the newest experimental epilepsy treatment - MIT Technology Review - April 3rd, 2024
- Global Regenerative Medicine Market to Touch Valuation of USD 472.95 Billion by 2032, at 25.86% CAGR: Astute ... - Yahoo Finance - April 1st, 2024
- Explosive Growth Projected for Stem Cell Market, Expected to Surpass $37 Billion by 2030 As Revealed In New... - WhaTech - April 1st, 2024
- Integrating New Therapies With Autologous Stem Cell Transplant in Myeloma - Targeted Oncology - April 1st, 2024
- New tool provides researchers with improved understanding of stem cell aging in the brain - Medical Xpress - March 30th, 2024
- The ISSCR announces 2024 election results - EurekAlert - March 28th, 2024
- Exosomes and Stem Cells Are the Future of Anti-Aging - NewBeauty Magazine - March 28th, 2024
- Charles River Extends Gene Therapy Alliance with NUS Medicine - Contract Pharma - March 22nd, 2024
- Exciting opportunities in stem cell technology and regenerative biology in Indian healthcare industry - Express Healthcare - March 22nd, 2024
- Charles River Announces Extension of Gene Therapy Manufacturing Alliance with NUS Yong Loo Lin School of Medicine - Yahoo Finance - March 22nd, 2024
- Opinion: The revolutionary sickle cell therapies - MSN - March 22nd, 2024
- 10 Years of Kansas Regenerative Medicine Center - KSAL - March 22nd, 2024
- BioCardia and StemCardia Announce Biotherapeutic Delivery Partnership - Diagnostic and Interventional Cardiology - March 17th, 2024
- Cynata Therapeutics' breakthrough in regenerative medicine - Finance News Network - March 17th, 2024
- New Positive Data Presented on Briquilimab Conditioning in Patients with Fanconi Anemia - GlobeNewswire - March 17th, 2024
- Novel 3D stem cell therapy to treat critical limb ischaemia - Drug Target Review - March 15th, 2024
- Breaking Boundaries: Pharmicell's Bold Vision for Healthcare Transformation and Monumental Growth - The Worldfolio - March 15th, 2024
- CuSTOM Organoid Research Evolving From Tool to Treatment - Research Horizons - Research Horizons - March 15th, 2024
- BioCardia and StemCardia Announce Partnership to Deliver Cell-Gene Therapy for Remuscularization of Heart - Cath Lab Digest - March 15th, 2024
- Calidi Biotherapeutics and City of Hope Announce Funding from the California Institute for Regenerative Medicine ... - Business Wire - March 13th, 2024
- Iron restriction keeps blood stem cells young, researchers find - Phys.org - March 13th, 2024
- Vitamin A could have a key role in both stem cell biology and wound healing: Study - Medical Dialogues - March 9th, 2024
- Trends in Stem Cell Transplantation Refusal for Myeloma Treatment - Targeted Oncology - March 7th, 2024
- Stem Cell Therapy Market (CAGR) of 31.1%, Future of Market Size Emerging Technologies and their Impact on ... - Taiwan News - March 7th, 2024
- This Swedish startup wants to reduce the cost, and controversy, around stem cell production - TechCrunch - March 6th, 2024
- Advancing stem cell therapy: The regulatory process to get to clinical trials - The Economic Times - March 6th, 2024
- Transitioning from traditional surgical methods to the innovative use of stem cells - pharmaphorum - March 6th, 2024
- 'Mini organs' are grown from human stem cells taken during the late stages of pregnancy for the first time - m - Daily Mail - March 6th, 2024
- Stem cell transplant cures man of HIV and leukemia, one of five to achieve full remission - Fox 28 - March 3rd, 2024
- Stem Cell Therapy Market to Boost USD 137.5 Billion by 2034 and Projected to grow at 32.10% CAGR with increasing ... - Yahoo Finance - March 1st, 2024
- Studies expand use of stem cell therapies - WPLG Local 10 - March 1st, 2024
- Innovative therapy targets and destroys leukemia stem cells - News-Medical.Net - February 27th, 2024
- Unlocking the Potential of Stem Cells: The Medical Revolution of the Century - EIN News - February 27th, 2024
- Pelage Pharmaceuticals Announces $16.75M Series A Financing led by GV to Revolutionize Regenerative Medicine ... - Yahoo Finance - February 27th, 2024
- Say Her Name - Henrietta Lacks, The Real Mother Of Stem - Her Campus - February 27th, 2024
- California Man Free of HIV And Cancer in Astonishing Medical Recovery - ScienceAlert - February 25th, 2024
- $93 million for research into improved health for children, young people and the aged, medical devices, mental health ... - Department of Health - February 25th, 2024
- Stem Cells in Regenerative Medicine - PMC - National Center for ... - February 24th, 2024
- The Promise and Reality of Stem Cell Therapy: What You Need to Know - Corporate Wellness Magazine - February 22nd, 2024
- Stem Cell Therapy: A Beacon of Hope for Patients with Untreatable Conditions - Corporate Wellness Magazine - February 22nd, 2024
- Leading Experts in Stem Cell Therapy: A Global Overview - Corporate Wellness Magazine - February 22nd, 2024
- Can Stem Cells Help Reverse the Effects of Aging? - Corporate Wellness Magazine - February 22nd, 2024
- Stem Cell Therapy for Cancer: Hope on the Horizon? - Corporate Wellness Magazine - February 22nd, 2024
- Stem Cells and Autism: A Closer Look at Innovative Treatments - Corporate Wellness Magazine - February 22nd, 2024
- Regrowth and Restoration: The Science Behind Stem Cell Therapy for Hair - Corporate Wellness Magazine - February 22nd, 2024
- Brain Recovery: The Role of Stem Cells in Stroke and Cerebral Palsy Treatments - Corporate Wellness Magazine - February 22nd, 2024
- Turning Back the Clock: The Science of Stem Cells in Anti-Aging - Corporate Wellness Magazine - February 22nd, 2024
- Insights into cellular therapies for cancer treatment - Drug Target Review - February 22nd, 2024
- The Role of Stem Cells in Rheumatoid Arthritis Recovery - Corporate Wellness Magazine - February 22nd, 2024
- Dr Ernesto Romeros vision transforms immunotherapy regenerative medicine into a global leader in stem cell treatment - Khaleej Times - February 22nd, 2024
- World-Renowned Doctors Leading the Way in Stem Cell Research and Treatment - Medical Tourism Magazine - February 20th, 2024
- Choosing the Best: A Guide to America's Premier Stem Cell Therapy Providers - Medical Tourism Magazine - February 20th, 2024
- Navigating Through the Possibilities of Stem Cell Treatment for Eye Disorders - Medical Tourism Magazine - February 20th, 2024
- Global Leaders in Stem Cell Therapy: Where Excellence Meets Innovation - Medical Tourism Magazine - February 20th, 2024
- Excellence in Stem Cell Treatment: How the US is Pioneering Global Healthcare Solutions - Medical Tourism Magazine - February 20th, 2024
- Clarifying Memory Loss Treatments: The Role of Stem Cells - Medical Tourism Magazine - February 20th, 2024
- Battling Inflammation: Stem Cell Therapy for Rheumatoid Arthritis - Medical Tourism Magazine - February 20th, 2024
- Digestive Health and Stem Cells: Treating Ulcerative Colitis and Crohn's Disease - Medical Tourism Magazine - February 20th, 2024
- Top Stem Cell Clinics in the USA: Pioneering Treatments for Chronic Conditions - Medical Tourism Magazine - February 20th, 2024
- Stem Cells and Autism: Understanding the Potential for Innovative Treatments - Medical Tourism Magazine - February 20th, 2024
- Stopping the awakening of sleeping Acute Myeloid Leukaemia stem cells to prevent disease relapse - University of Birmingham - February 20th, 2024
- City of Hope Achieves Ground Breaking Treatment for Blood Cancer and HIV - Medriva - February 18th, 2024
- Regenerative Medicine Market Size to Worth USD 95 Billion by 2032 - InvestorsObserver - February 18th, 2024
- North America Organoids Market Projected to Reach US$ 5.35 Billion by 2030, Riding on a CAGR of 21.5% - GlobeNewswire - February 18th, 2024
- Chinese team tests lung treatment that may be first to reverse COPD damage - South China Morning Post - February 15th, 2024
Recent Comments